Synthesis, crystal structure analysis, spectral investigations (NMR, FT-IR, UV), DFT calculations, ADMET studies, molecular docking and anticancer activity of 2-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine – A novel potent human topoisomerase IIα inhibitor

Add time:07/20/2019    Source:sciencedirect.com

Previous research studies confirm that molecules containing 1,2,3-triazole moiety are potential anticancer agents which elevates effectiveness and reduces drug resistance. Present study was aimed to evaluate the anticancer activity of the synthesized novel title compound 2-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine (BTCP). The structural and spectral characteristics of BTCP were studied and compared with DFT results. NBO, HOMO and LUMO energies, Mulliken atomic charges and molecular electrostatic potential surface were investigated. The bioavailability of BTCP was confirmed by pharmacological investigations using Molinspiration and PreADMET online servers. Molecular docking studies verified the inhibitory nature of BTCP against human topoisomerase IIα enzyme (1ZXM) over standard drug doxorubicin. MTT assay technique has been employed to study anticancer activity of BTCP with three human cancer cell lines (A549, MDAMB-231, PC-3) along with existing drug doxorubicin. The results of docking and anticancer activity specify that BTCP could be regarded as an alternative anticancer drug.

We also recommend Trading Suppliers and Manufacturers of N-(2-Methyl-5-chlorophenyl)-4,5-dihydro-1H-imidazole-2-amine (cas 16822-85-8). Pls Click Website Link as below: cas 16822-85-8 suppliers

Prev:Pharmacological evidence for the relationship between the NMDA receptor and nitric oxide pathway and the antidepressant-like effects of glucagon-like peptide-2 in the mouse forced-swim test
Next:The P-glycoprotein inhibitor diltiazem-like 8-(4-chlorophenyl)-5-methyl-8-[(2Z)-pent-2-en-1-yloxy]-8H-[1,2,4]oxadiazolo[3,4-c][1,4]thiazin-3-one inhibits esterase activity and H3 histone acetylation)